Department of Radiology, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Xi-Cheng District, Beijing, China.
Acad Radiol. 2013 Jan;20(1):25-31. doi: 10.1016/j.acra.2012.07.014. Epub 2012 Sep 2.
The aim of this study was to evaluate whether matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) are elevated in patients with nonobstructive coronary artery disease.
Eighty-four patients with nonobstructive coronary artery disease (group A) and 90 patients with no coronary plaques (group B) were enrolled. MMP-9 and MPO levels were compared between the two groups. The relationships between these biomarkers and Framingham risk score were analyzed. Receiver-operating characteristic curves were used to evaluate the ability of these biomarkers to predict the presence of coronary artery plaques.
The MMP-9 and MPO values in group A were significantly higher than in group B (P < .001). The levels of MMP-9 and MPO showed significant correlations with Framingham risk score (r = 0.796, P < .001, and r = 0.409, P < .001, respectively). The areas under the receiver-operating characteristic curves for MMP-9 and MPO were 0.80 (95% confidence interval, 0.74-0.87) and 0.74 (95% confidence interval, 0.66-0.81), respectively.
Levels of MMP-9 and MPO are positively correlated with Framingham risk score. Additionally, in patients with nonobstructive coronary artery disease, elevated levels of MMP-9 and MPO may identify patients at risk for future myocardial infarction or sudden cardiac death.
本研究旨在评估基质金属蛋白酶-9（MMP-9）和髓过氧化物酶（MPO）是否在非阻塞性冠状动脉疾病患者中升高。
纳入 84 例非阻塞性冠状动脉疾病患者（A 组）和 90 例无冠状动脉斑块患者（B 组）。比较两组患者 MMP-9 和 MPO 水平。分析这些生物标志物与弗莱明汉风险评分的关系。使用受试者工作特征曲线评估这些生物标志物预测冠状动脉斑块存在的能力。
A 组 MMP-9 和 MPO 值明显高于 B 组（P<0.001）。MMP-9 和 MPO 水平与弗莱明汉风险评分呈显著相关（r=0.796，P<0.001，r=0.409，P<0.001）。MMP-9 和 MPO 的受试者工作特征曲线下面积分别为 0.80（95%置信区间，0.74-0.87）和 0.74（95%置信区间，0.66-0.81）。
MMP-9 和 MPO 水平与弗莱明汉风险评分呈正相关。此外，在非阻塞性冠状动脉疾病患者中，MMP-9 和 MPO 水平升高可能提示未来心肌梗死或心源性猝死的风险。
